Conduent (CNDT) Q2 2026 earnings review
Divestitures Execute, But Core Business Hemorrhages
Conduent successfully announced the sale of its Transportation segment (Transit and Tolling) for roughly $234 million in proceeds, marking a major milestone in its turnaround and portfolio optimization plan. However, the remaining core business (Continuing Operations) is struggling significantly. Total revenue dropped 11.9% YoY to $531 million, a sharp deceleration from the ~5% declines seen in recent quarters. Adjusted EBITDA margin plummeted sequentially to 3.0%. While management is guiding for robust full-year EBITDA driven by a massive $100M cost-reduction program, the aggressive top-line deterioration raises significant execution risks for the transformation.
🐂 Bull Case
Agreements to sell the Transit and Tolling businesses will generate $234M in gross proceeds (plus a 7% equity stake). This provides crucial capital to pay down debt and shrinks the company's bloated focus.
Management's $100M+ annualized cost-savings program is progressing. Full-year guidance implies severe margin expansion in the back half of the year despite lower volumes.
🐻 Bear Case
Top-line declines worsened dramatically from -5.0% in 26Q1 to -11.9% in 26Q2. Both the Commercial (-9.7%) and Government (-13.4%) segments are losing volume.
Adjusted EBITDA margin for continuing ops crashed to 3.0% in Q2, down from 8.5% just one quarter prior, indicating severe negative operating leverage.
⚖️ Verdict: 🔴
Bearish. While the new CEO is delivering on promises to divest non-core assets and attack costs, the underlying organic business is shrinking at an alarming rate. A turnaround cannot rely on cost-cutting alone when revenue drops 12% in a single quarter.
Key Themes
Transportation Divestitures Finalized
Conduent officially classified its Transportation businesses as Discontinued Operations after agreeing to sell Public Transit to Modaxo ($164M) and Tolling to Quarterhill ($70M + 7% equity). This exceeds the company's $200M target and provides necessary liquidity to deleverage a balance sheet that currently sits at 2.1x adjusted net leverage.
Commercial Segment Hemorrhaging
The Commercial segment remains a massive drag on the overall business. Revenue fell 9.7% YoY to $316M. The decline was primarily driven by contract losses and the previously communicated loss of their largest Commercial customer. Segment margins held relatively stable at 7.6% (up 20 bps YoY) due to strict cost efficiencies, but the top-line erosion is severe.
Government Segment Reverses to Decline
Historically the more stable segment, Government experienced a sharp reversal, with revenue plunging 13.4% YoY to $215M. Management blamed contract losses, lower volumes, and timing of implementations in Government Healthcare Solutions. Adding to the pain, the segment's Adjusted EBITDA margin contracted by 150 bps YoY down to 23.7%.
New Business Pipeline Fails to Offset Losses
Despite management's focus on converting pipeline, Q2 New Business ACV was only $99M, down from $111M a year ago. Average contract lengths have also compressed to 2.3 years from 2.7 years a year ago, providing less long-term revenue visibility.
AI and Next-Gen Healthcare Investments
Conduent rolled out an AI-powered next-generation Customer Experience platform featuring real-time translation and voice enhancement. Crucially, they are also investing in next-gen Medicaid technology for provider enrollment, scoring a multi-year contract renewal in Virginia (1.6M members) and a modernized Medicaid platform launch in New Mexico (900K members).
Other KPIs
FCF remains negative but is accelerating positively compared to the $(30)M burn in 26Q2. The improvement was driven by favorable working capital results and realization of long-term projects. The company remains highly focused on converting to positive FCF by 2027.
Decelerating. This figure represents a slight increase from $60M a year ago, but total TCV signings (which include renewals) collapsed to $194M from $466M in the prior year period. A significant drop in renewal bookings is a leading indicator of further revenue pressure.
Guidance
Decelerating. Based on FY25 continuing operations revenue of $2.43B, the $2.20B midpoint implies a YoY organic revenue decline of approximately 9.6%. This reflects the deep cuts in the Commercial segment and slower Government conversions.
Accelerating. Despite the massive projected drop in revenue, the midpoint of $155M represents a 26% YoY increase compared to FY25's $123M. To hit this, Conduent must execute flawlessly on its $100M cost reduction targets in the second half of the year to offset the volume declines.
Key Questions
Bridging the H2 EBITDA Gap
With Q1 at $50M and Q2 at $16M, H1 Adjusted EBITDA sits at $66M. The guidance midpoint of $155M requires $89M in H2. How much of this relies on the $100M structural cost-out program versus assumed improvements in underlying margins?
Government Segment Volatility
The Government segment shifted from a pillar of stability to a 13.4% YoY decline. Are these implementation delays purely timing issues that will catch up in H2, or has the competitive win-rate fundamentally shifted?
Capital Allocation Post-Divestiture
With $234M in gross proceeds expected from the Transportation divestitures, exactly how will these funds be prioritized between the $697M in long-term debt, working capital needs, and shareholder returns?